Arkolith/Insider Trading/ORMP/Form 4

Gabay Avraham

Chief Financial OfficerORAMED PHARMACEUTICALS INC. (ORMP) · full profile →Form 4 · filed Jan 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2025Grant(A)115K—$0630K
Dec 31, 2025Grant(A)81K—$0515K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2025Grant(A)19K—$019K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-26-000658) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML